Author Archives: Inês Martins PhD

Cushing’s Disease Patients with USP8 Mutations More Likely to Achieve Remission After Surgery, Study Finds

Cushing’s disease patients whose pituitary tumors carry a USP8 mutation are more likely to achieve remission after surgery than those without such mutations, a retrospective Italian study found. The study, “Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas,” was published in the journal…

Fluasterone Receives Orphan Drug Status for the Treatment of Hallmark Signs of Cushing’s Syndrome

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and high blood sugar in Cushing’s syndrome patients, SteroTherapeutics announced. Cushing’s syndrome occurs when the body is exposed to high levels of the hormone cortisol over a long period.